Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|182706-5MG||Glass bottle||5 mg||
|Overview||A cell-permeable purine compound that acts as a high affinity AhR antagonist (IC50 = 127 nM against 3 nM TCDD-induced luciferase reporter activity in HepG2 cultures), but not a panel of 61 kinases. AhR expression and function knockouts by shRNAs, CH-223191 (Cat. No. 182705), or SR1 treatment all result in enhanced and sustained CD34+ population in long-term proliferating/expanding cultures of cord blood-derived HSCs (hematopoietic setem cells) in serum-free media containing Tpo (Cat. No. 605218), SCF (Cat. No. 569600), Flt3 Ligand (Cat. No. 343010), and IL-6 (Cat. No. 407652) in a reversible manner. SR1 is reactive toward human, monkey, and canine, but not rat or murine, species.|
|Synonyms||4-(2-(2-(Benzo[b]thiophen-3-yl)-9-isopropyl-9H-purin-6-ylamino)ethyl)phenol, 4-[2-[[2-Benzo[b]thien-3-yl-9-(1-methylethyl)-9H-purin-6-yl]amino]ethyl]phenol, StemRegenin 1|
|References||Boitano, A.E., et al. 2010. Science 329, 1345.|
|Structure formula Image|
|Purity||≥98% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
AhR Antagonist II, SR1 - CAS 1227633-49-10 - Calbiochem SDS
|Boitano, A.E., et al. 2010. Science 329, 1345.|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.